Roche agreed to acquire PathAI for $750 million upfront plus up to $300 million in milestone payments, totaling up to $1.05 billion.
The deal aims to integrate PathAI's AI tools for digital pathology into Roche's oncology diagnostics platforms.
Acquisition expected to close in the second half of 2026, subject to regulatory approvals.
PathAI specializes in AI models for tissue sample analysis and digital pathology workflows.
Roche and PathAI have partnered since 2021, expanding in 2024 for AI companion diagnostics.